Share This Page
Drug Price Trends for MILI
✉ Email this page to a colleague
Average Pharmacy Cost for MILI
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MILI 0.25-0.035 MG TABLET | 65862-0776-28 | 0.12836 | EACH | 2025-03-19 |
| MILI 0.25-0.035 MG TABLET | 65862-0776-85 | 0.12836 | EACH | 2025-03-19 |
| MILI 0.25-0.035 MG TABLET | 65862-0776-28 | 0.12083 | EACH | 2025-02-19 |
| MILI 0.25-0.035 MG TABLET | 65862-0776-85 | 0.12083 | EACH | 2025-02-19 |
| MILI 0.25-0.035 MG TABLET | 65862-0776-85 | 0.11180 | EACH | 2025-01-22 |
| MILI 0.25-0.035 MG TABLET | 65862-0776-28 | 0.11180 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Anti-Obesity Drugs: A Focus on MILI and Similar Therapies
Introduction to the Anti-Obesity Drug Market
The global market for anti-obesity medications (AOMs) is on the cusp of a significant transformation, driven by increasing obesity rates and the emergence of more effective treatments. Here, we delve into the market analysis and price projections for anti-obesity drugs, with a particular focus on therapies like MILI (semaglutide and similar GLP-1 receptor agonists).
Current Market Size and Growth Projections
As of 2023, the global market for AOMs has reached $6 billion annually. However, this figure is expected to skyrocket to $100 billion by 2030, representing a growth of more than 16 times over the next seven years, according to Goldman Sachs Research[1].
Drivers of Market Growth
Several factors are driving this exponential growth:
Increasing Obesity Rates
Obesity rates have almost tripled worldwide since 1975, with over half of the global population projected to be overweight or obese by 2035. This rising prevalence is a significant driver of the demand for effective anti-obesity treatments[1].
Insurance Reimbursement and Drug Pricing
The rate of insurance reimbursement, the duration of use among patients, and drug pricing are crucial factors influencing the market. As more insurance providers cover these medications, and with the potential for longer treatment durations, the market is poised for substantial growth[1].
Advancements in Therapies
The introduction of new and more effective therapies, such as incretin-mimetics like GLP-1 receptor agonists (e.g., semaglutide), has significantly improved weight loss outcomes. These drugs can achieve weight loss up to the mid-20% range, far surpassing the modest 3% to 11% body weight reduction of earlier generation therapies[1].
Key Players in the Market
Companies like Eli Lilly and Novo Nordisk are expected to dominate the AOM market. These companies have developed and are continuously improving GLP-1 receptor agonists, which are at the forefront of anti-obesity treatment innovations[1].
Economic Impact of Obesity
The economic burden of obesity is substantial. In the US, obesity-related medical costs were estimated at $173 billion in 2019. Globally, the total costs associated with obesity, including healthcare and productivity losses, are projected to exceed $4 trillion by 2035, or about 3% of global GDP[1].
Market Sensitivity and Uncertainties
The $100 billion forecast is relatively sensitive to minor tweaks in underlying drivers such as patient population, insurance reimbursement rates, and drug pricing. This sensitivity underscores the need for careful market analysis and continuous monitoring of these factors[1].
Impact of Regulatory Changes
Regulatory changes, such as those brought about by the Inflation Reduction Act, can influence drug spending patterns. For instance, provisions aimed at reducing drug costs and capping out-of-pocket spending can impact the overall market dynamics, although these changes are more broadly applicable to the prescription drug market rather than specifically to AOMs[2].
Comparison with Other Pharmaceutical Markets
To put the growth of the AOM market into perspective, it is useful to compare it with other pharmaceutical markets. For example, the pain management drugs market is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033. While this market is significant, the growth rate and total market size of AOMs are expected to be more dramatic due to the escalating obesity crisis[4].
Clinical and Therapeutic Advancements
The next generation of AOMs is expected to deliver even better results. These advancements include improved formulations, better delivery systems, and potentially new mechanisms of action that could further enhance weight loss outcomes and patient compliance[1].
Patient Population and Treatment Penetration
By 2030, approximately 15 million adults in the US alone may be treated with AOMs, representing about 13% penetration of the eligible US obese/overweight adult population. This significant penetration rate underscores the potential market size and the growing demand for these treatments[1].
Key Takeaways
- The global anti-obesity drug market is projected to grow from $6 billion in 2023 to $100 billion by 2030.
- Increasing obesity rates, advancements in therapies, and favorable insurance reimbursement are key drivers of this growth.
- Companies like Eli Lilly and Novo Nordisk are expected to be major players in this market.
- The economic burden of obesity is substantial, and reducing obesity rates could alleviate significant healthcare and productivity costs.
- The market is sensitive to changes in underlying drivers such as patient population, insurance reimbursement, and drug pricing.
Frequently Asked Questions
Q: What is the current size of the global anti-obesity drug market? A: The global market for anti-obesity medications (AOMs) reached $6 billion on an annualized basis as of 2023[1].
Q: How much is the anti-obesity drug market expected to grow by 2030? A: The market is forecasted to grow to $100 billion by 2030, representing a growth of more than 16 times over the next seven years[1].
Q: What are the main drivers of the growth in the anti-obesity drug market? A: Key drivers include increasing obesity rates, advancements in therapies like GLP-1 receptor agonists, and favorable insurance reimbursement rates[1].
Q: Which companies are expected to dominate the anti-obesity drug market? A: Eli Lilly and Novo Nordisk are expected to be major players in this market due to their development of effective GLP-1 receptor agonists[1].
Q: What is the economic impact of obesity, and how could reducing obesity rates help? A: Obesity-related medical costs are substantial, with global costs projected to exceed $4 trillion by 2035. Reducing obesity rates could alleviate significant healthcare and productivity costs[1].
Sources:
- Goldman Sachs Research: "Why the anti-obesity drug market could grow to $100 billion by 2030"[1]
- Health System Tracker: "What are the recent and forecasted trends in prescription drug spending?"[2]
- The Business Research Company: "Global Multiple Myeloma Drugs Market Report 2024"[3]
- Allied Market Research: "Pain Management Drugs Market Size, Share | Forecast - 2033"[4]
- PubMed: "National trends in prescription drug expenditures and projections for 2023"[5]
More… ↓
